Geode Capital Management LLC Has $32.50 Million Stock Position in Harrow, Inc. (NASDAQ:HROW)

Geode Capital Management LLC boosted its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 0.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 722,730 shares of the company’s stock after purchasing an additional 3,960 shares during the period. Geode Capital Management LLC’s holdings in Harrow were worth $32,500,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Quest Partners LLC acquired a new stake in shares of Harrow in the 3rd quarter valued at approximately $29,000. nVerses Capital LLC bought a new position in shares of Harrow in the 2nd quarter valued at about $33,000. Allspring Global Investments Holdings LLC increased its stake in shares of Harrow by 2,730.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after purchasing an additional 2,048 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares during the period. Finally, Hills Bank & Trust Co acquired a new stake in Harrow in the 3rd quarter valued at about $107,000. 72.76% of the stock is currently owned by institutional investors.

Harrow Price Performance

Shares of NASDAQ HROW opened at $33.83 on Thursday. The firm has a market cap of $1.20 billion, a P/E ratio of -35.99 and a beta of 0.69. The business’s 50 day moving average is $43.82 and its 200-day moving average is $37.01. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 1-year low of $9.13 and a 1-year high of $59.23.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HROW shares. Lake Street Capital upped their price objective on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Craig Hallum lifted their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley dropped their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.